Intriguingly, a recent study showed that anthracyclines are able to trigger type I IFN signalling in murine sarcoma, mammary carcinoma and leukemia cell lines, including the transcription of several Interferon stimulated-genes (ISGs) and also of PLSCR2 [34]. This evidence concerns the gene PLSCR2 and breast carcinoma.